Market Closed -
Other stock markets
|
After market 03:01:23 pm | |||
90.96 EUR | -0.87% | 90.24 | -0.79% |
01:29pm | SANOFI : Barclays reiterates its Buy rating | ZD |
10:38am | Smith & Nephew CFO designate John Rogers to start next week | AN |
Sales 2024 * | 46.44B 50.19B | Sales 2025 * | 50.22B 54.28B | Capitalization | 115B 124B |
---|---|---|---|---|---|
Net income 2024 * | 7.34B 7.93B | Net income 2025 * | 8.67B 9.37B | EV / Sales 2024 * | 2.62 x |
Net Debt 2024 * | 6.96B 7.52B | Net Debt 2025 * | 2.43B 2.63B | EV / Sales 2025 * | 2.33 x |
P/E ratio 2024 * |
15.2
x | P/E ratio 2025 * |
12.9
x | Employees | 86,088 |
Yield 2024 * |
4.18% | Yield 2025 * |
4.54% | Free-Float | 87.77% |
Latest transcript on Sanofi
1 day | -0.56% | ||
1 week | +4.04% | ||
Current month | +3.82% | ||
1 month | +2.71% | ||
3 months | +2.23% | ||
6 months | -9.44% | ||
Current year | +1.66% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Hudson
CEO | Chief Executive Officer | 56 | 19-08-31 |
Director of Finance/CFO | 59 | 18-09-30 | |
Nestle Frank
CTO | Chief Tech/Sci/R&D Officer | - | 16-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Kron
BRD | Director/Board Member | 70 | 14-04-30 |
Lise Kingo
BRD | Director/Board Member | 62 | 20-04-27 |
Gilles Schnepp
BRD | Director/Board Member | 64 | 20-05-21 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
6.31% | 5 M€ | +4.56% | ||
3.66% | 129 M€ | -.--% | - | |
3.55% | 264 M€ | +13.50% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 90.96 | -0.87% | 1 839 942 |
24-03-27 | 91.76 | +0.50% | 1,234,665 |
24-03-26 | 91.3 | +1.84% | 1,589,467 |
24-03-25 | 89.65 | +1.13% | 1,169,107 |
24-03-22 | 88.65 | +1.07% | 1,869,167 |
Real-time Euronext Paris, March 28, 2024 at 10:47 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.66% | 124B | |
+35.82% | 701B | |
+26.24% | 571B | |
+1.14% | 381B | |
+20.46% | 334B | |
+16.89% | 319B | |
+0.87% | 210B | |
+2.32% | 210B | |
-6.38% | 201B | |
-3.21% | 157B |